The funds most exposed to struggling AstraZeneca

Third quarter results showed disappointing results for pharmaceuticals giant AstraZeneca, with shares falling 5 per cent. Ketan Patel, fund manager at EdenTree talks to Trustnet about why this may not be such bad news for the pharmaceutical sector, as sales in AstraZeneca’s growth platform – including emerging markets, diabetes and oncology – are remaining strong.

Link

top